• Featured Product
  • KD/KO Validated

Amphiregulin Polyclonal antibody

Amphiregulin Polyclonal Antibody for FC, IF, IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG







Cat no : 16036-1-AP


amphiregulin, AR, AREG, AREGB, CRDGF, SDGF

Tested Applications

Positive WB detected inMCF-7 cells, A549 cells, HepG2 cells
Positive IP detected inHepG2 cells
Positive IHC detected inhuman colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inhuman colon cancer tissue
Positive FC detected inHeLa cells
Planning an IF experiment? We recommend our CoraLite®488 and CoraLite®647 conjugated versions of this antibody.

Recommended dilution

Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:1000-1:4000 for WB
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

16036-1-AP targets Amphiregulin in WB, IP, IHC, IF, FC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Amphiregulin fusion protein Ag8907
Full Name amphiregulin
Calculated molecular weight 252 aa, 28 kDa
Observed molecular weight 43 kDa
GenBank accession numberBC009799
Gene symbol AREG
Gene ID (NCBI) 374
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Amphiregulin (AREG) is one of the ligands of the epidermal growth factor receptor (EGFR). AREG plays a central role in mammary gland development and branching morphogenesis in organs and is expressed both in physiological and in cancerous tissues. The AREG protein is synthesized as a 252-amino acid transmembrane precursor, pro-AREG. At the plasma membrane, pro-AREG is subjected to sequential proteolytic cleavages within its ectodomain and is then released as the soluble AREG protein. Depending on the cell type and microenvironment, AREG can be produced in multiple cellular and mature forms using alternative pro-AREG cleavage sites and glycosylation motifs. Post-translastional modfications of 50-kDa pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa membrane anchored forms, and soluble 21-, 19-, and 9-kDa forms (PMID: 9642297).


Product Specific Protocols
WB protocol for Amphiregulin antibody 16036-1-APDownload protocol
IHC protocol for Amphiregulin antibody 16036-1-APDownload protocol
IF protocol for Amphiregulin antibody 16036-1-APDownload protocol
IP protocol for Amphiregulin antibody 16036-1-APDownload protocol
FC protocol for Amphiregulin antibody 16036-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols




Loss of KIBRA function activates EGFR signaling by inducing AREG.

Authors - Ashley L Mussell

Mol Clin Oncol

Establishment of a patient-derived mucoepidermoid carcinoma cell line with the CRTC1-MAML2 fusion gene.

Authors - Kazuma Noguchi

J Cancer

CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma.

Authors - Jiakai Mao

Biomed Pharmacother

IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.

Authors - Hongning Cai


AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells.

Authors - Zhiguang Xiao

Mol Cancer Res

Extracellular Matrix-Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer.

Authors - Josh W DiGiacomo